Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

HHS newborn screening panel: Recommendation that all newborns be screened for 29 rare medical conditions will be discussed when the Advisory Committee on Heritable Disorders & Genetic Diseases in Newborn & Children convenes April 21-22 in Washington, D.C. A report elucidating the proposed recommendations will be published the week of Feb. 28 in the Federal Register, with comments due the week of May 1. The committee has dropped a test for G6PD deficiency from the recommended test panel, citing insufficient evidence to justify screening (1"The Gray Sheet" Sept. 27, 2004, p. 6)...

You may also be interested in...



Expanded Newborn Screening Recommended By HHS Advisory Committee

HHS is one step closer to establishing national guidelines advising which tests should be added to state-mandated newborn screening programs

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel